---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-012021"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:05:25.604418+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics gets FDA clearance for Phase 1 trial of HCW9302 in alopecia areata

## Summary
- FDA cleared IND for HCW9302, a first-in-class IL-2 fusion protein, in moderate-to-severe alopecia areata.
- Phase 1 dose-escalation trial will evaluate safety and T reg cell expansion via subcutaneous injection.
- No curative FDA-approved treatments currently exist for alopecia areata.
- Company plans to expand clinical development to other autoimmune diseases after Phase 1.
- Founder and CEO Hing C. Wong called the clearance a milestone for the company.

## SEC filing metadata
- accession: 0000950170-25-012021
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025012021/0000950170-25-012021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025012021/hcwb-20250203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-012021
- JSON: https://secwatch.observer/filing/0000950170-25-012021.json
- Plain text: https://secwatch.observer/filing/0000950170-25-012021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.